Table 4.
Malignant tumour 3-year and 5-year relative survival and its 95% CI in the Augsburg study region by sex and site— incident cases of the years 2005–2011 (n=21 493)
| Site (ICD-10) | Men | Women | ||
| 3-year RES (95% CI) |
5-year RES (95% CI) |
3-year RES (95% CI) |
5-year RES (95% CI) |
|
| Lip/oral cavity/pharynx (C00–C14) | 49.6 (44.8 to 54.9) | 43.2 (38.4 to 48.7) | 66.5 (58.4 to 75.8) | 61.0 (52.3 to 71.2) |
| Oesophagus (C15) | 30.3 (24.7 to 37.3) | 25.7 (20.2 to 32.7) | 37.6 (25.8 to 54.8) | 23.9 (14.0 to 40.8) |
| Stomach (C16) | 44.3 (39.2 to 50.0) | 41.4 (36.0 to 47.5) | 47.1 (41.1 to 54.0) | 43.4 (37.0 to 50.8) |
| Colorectum (C18–C21) | 74.6 (72.2 to 77.2) | 69.3 (66.5 to 72.3) | 73.4 (70.6 to 76.4) | 70.4 (67.2 to 73.7) |
| Liver (C22) | 18.9 (14.4 to 24.8) | 14.1 (10.0 to 19.7) | 28.5 (19.7 to 41.3) | 19.8 (12.2 to 32.1) |
| Gallbladder/biliary tract (C23–C24) | 33.8 (24.3 to 47.2) | 24.5 (15.7 to 38.4) | 20.5 (14.0 to 30.0) | 16.4 (10.5 to 25.7) |
| Pancreas (C25) | 9.8 (6.9 to 13.8) | 6.4 (4.1 to 10.1) | 11.9 (8.6 to 16.4) | 10.2 (7.1 to 14.6) |
| Larynx (C32) | 72.2 (64.3 to 81.1) | 65.0 (56.3 to 75.1) | 47.6 (28.1 to 80.7) | 49.0 (28.9 to 83.0) |
| Lung (C33–C34) | 21.0 (18.7 to 23.5) | 18.1 (15.9 to 20.6) | 27.1 (23.6 to 31.0) | 20.8 (17.6 to 24.5) |
| Malignant melanoma of the skin (C43) | 95.6 (92.8 to 98.5) | 95.3 (91.8 to 99.0) | 98.1 (95.9 to 100.4) | 96.6 (93.6 to 99.6) |
| Mesothelioma (C45) | 24.3 (15.0 to 39.3) | 18.0 (9.7 to 33.3) | 30.2 (11.1 to 82.3) | 32.4 (11.9 to 88.3) |
| Soft tissue without mesothelioma (C46–C49) | 67.6 (58.4 to 78.2) | 69.8 (60.0 to 81.3) | 69.5 (60.2 to 80.2) | 63.0 (53.1 to 74.8) |
| Breast (C50) | 69.0 (49.6 to 95.8) | 61.0 (40.6 to 91.8) | 91.7 (90.4 to 92.9) | 88.6 (87.1 to 90.1) |
| Vulva (C51) | 67.8 (58.3 to 78.8) | 62.6 (52.3 to 74.8) | ||
| Cervix uteri (C53) | 71.4 (65.0 to 78.3) | 67.2 (60.5 to 74.7) | ||
| Corpus uteri (C54–C55) | 85.4 (81.9 to 89.1) | 82.5 (78.4 to 86.8) | ||
| Ovary (C56) | 48.0 (43.2 to 53.3) | 40.2 (35.5 to 45.6) | ||
| Prostate (C61) | 96.5 (95.1 to 97.9) | 97.7 (96.0 to 99.4) | ||
| Testis (C62) | 97.4 (94.8 to 100.0) | 97.2 (94.5 to 100.0) | ||
| Kidney (C64) | 81.9 (77.1 to 87.0) | 79.8 (74.3 to 85.7) | 76.6 (70.6 to 83.1) | 76.2 (69.6 to 83.4) |
| Urinary bladder (C67) | 61.3 (55.6 to 67.5) | 58.1 (51.8 to 65.1) | 48.4 (40.1 to 58.4) | 48.4 (39.6 to 59.3) |
| Central nervous system (C70–C72) | 29.2 (23.1 to 37.0) | 24.2 (18.5 to 31.7) | 33.3 (26.2 to 42.3) | 28.1 (21.4 to 36.9) |
| Thyroid (C73) | 96.5 (91.5 to 101.8) | 95.1 (89.2 to 101.5) | 95.3 (92.5 to 98.2) | 95.9 (92.9 to 99.0) |
| CUP (C80) | 18.8 (13.9 to 25.3) | 16.0 (11.3 to 22.6) | 17.6 (12.8 to 24.1) | 15.8 (11.0 to 22.7) |
| Hodgkin’s lymphoma (C81) | 89.2 (81.6 to 98.0) | 87.6 (78.8 to 97.4) | 92.3 (84.0 to 101.4) | 94.2 (85.7 to 103.6) |
| Non-Hodgkin’s lymphoma (C82–C88) | 75.5 (70.8 to 80.5) | 73.2 (68.0 to 78.8) | 75.3 (70.5 to 80.5) | 74.6 (69.3 to 80.3) |
| Multiple myeloma (C90) | 59.5 (51.4 to 68.8) | 53.0 (44.5 to 63.2) | 58.7 (50.6 to 68.1) | 47.5 (39.2 to 57.7) |
| Leukaemia (C91–C95) | 70.3 (64.8 to 76.3) | 67.2 (61.2 to 73.9) | 65.8 (59.7 to 72.6) | 62.5 (55.9 to 69.7) |
APC, annual percent change; RES, relative survival (%).